Project title
利用eCD16A/anti-CD3-BFP將內源性癌症辨識抗體轉化為T細胞重導向雙功能性抗體:新穎免疫治療策略之概念確認性探索
Internal ID
NSTC113-2314-B002-104-MY2
Principal Investigator
Start Date
August 1, 2024
End Date
July 31, 2025
Investigators
Organizations
Partner Organizations
Transforming Endogenous Cancer-Targeting Antibodies into T Cell Redirecting Bifunctional Antibodies with Ecd16a/Anti-Cd3-Bfp: Proof-Of-Concept Explorations of a Novel Immunotherapy Strategy
Keywords
bifunctional antibody
endogenous antibody
cancer immunotherapy
EB virus
Description
eCD16A/anti-CD3-BFP雙功能性抗體可轉化內源性抗體成為可毒殺癌細胞之治療性抗體，引導T細胞至腫瘤處毒殺癌細胞。此研究除可拓展癌症免疫治療之策略，並可有未來臨床及商業發展潛力，造福更多病患。